Dorsal micetoma caused by Nocardia brasiliensis. A case report of a patient treated with imipenem and amikacin;Micetoma dorsal por Nocardia brasiliensis. Descripción de un caso tratado con imipenem y amikacina

Dermatologia Revista Mexicana

Volumn 49, Issue 4, 2005, Pages 178-181

  Fernández, Ramón Felipe ^a   Arenas, Roberto ^a   Reyes, Miguel ^a   Zacarías, Rogelio ^a  

^a HOSPITAL GENERAL DR MANUEL GEA GONZÁLEZ   (Mexico)

Author keywords

Amikacin; Imipenem; Mycetoma; Nocardia brasiliensis

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; COTRIMOXAZOLE; DAPSONE; GARENOXACIN; GATIFLOXACIN; IMIPENEM; ISEPAMICIN; MINOCYCLINE; MOXIFLOXACIN; OXAZOLIDINE DERIVATIVE; TETRACYCLINE;

ADULT; ANAMNESIS; ARTICLE; BODY WEIGHT; CASE REPORT; CLINICAL FEATURE; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYCETOMA; NOCARDIA BRASILIENSIS; SKIN BIOPSY; TREATMENT DURATION; TREATMENT OUTCOME;

EID: 35348901272     PISSN: 01854038     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. a ed. México: Interamericana McGraw- Hill, 2003;pp:113-27.
2. Steingrube VA, Wallace RJ Jr, Brown VA, et al. Acquired resistance to Nocardia brasiliensis to clavulanic acid related to a change in beta-lactamase following therapy with amoxicillin-clavulanic acid. Antimicrob Agents Chemother 1991;35(3):524-8.
3. Kageyama A, Hoshino Y, Watanabe M, et al. Clinical isolates of Nocardia brasiliensis from Japan exhibit variable susceptibility to the antibiotic imipenem. Mycopathologia 2004;158(3):275-8.
4. Baril L, Boiron P, Manceron V, et al. Refractory craneofacial actinomycetoma due to Streptomyces somaliensis that required salvage therapy with amikacin and imipenem. Clin Infect Dis 1999;29:460-1.
5. Primaxin® I.V. (Merck) (Imipenem and Cilastatin for Injection) 7882128 Issued August 2003 Copyright© Merck & Co., Inc., 1987, 1994, 1998 Copyright © 2002-2005 Thomson PDR.
6. Adamis G, Papaioannou MG, Giamarellos-Bourboulis EJ, et al. Pharmacokinetic interactions of ceftazidime, imipenem and aztreonam with amikacin in healthy volunteers. Int J Antimicrob Agents 2004;23(2):144-9.
7. McNeil MM, Brown JM, Jarvis WR, Ajello L. Comparison of species distribution and microbial susceptibility of aerobic actinomycetes from clinical specimens. Rev Infect Dis 1990;12(5):778-83.
8. Khardori N, Shawar R, Gupta R, et al. In vitro antimicrobial susceptibilities of Nocardia species. Antimicrob Agents Chemother 1993;37(4):882-4.
9. Yazawa K, Mikami Y, Ohashi S, et al. In-vitro activity of new carbapenem antibiotics: comparative studies with meropenem, L-627 and imipenem against pathogenic Nocardia spp. J Antimicrob Chemother 1992;29(2):169-72.
10. Blaser J. Interactions of antimicrobial combinations in vitro: the relativity of synergism. Scand J Infect Dis Suppl 1990;74:71-79.
11. Vera-Cabrera L, Gómez-Flores A, Escalante-Fuentes WG, Welsh O. In vitro activity of PNU-100766 (linezolid), a new oxazolidinone antimicrobial, against Nocardia brasiliensis. Antimicrob Agents Chemother 2001;45(12):3629-30.
12. Vera-Cabrera L, González E, Choi SH, Welsh O. In vitro activities of new antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004;48(2):602-4.
13. Gomez-Flores A, Welsh O, Said-Fernández S, et al. In vitro and in vivo activities of antimicrobials against Nocardia brasiliensis. Antimicrob Agents Chemother 2004;48(3):832-7.
14. Mendez-Tovar LJ, Serrano-Jaen L, Almeida-Arvizu VM. Combined cefotaxime and amikacin for immunomodulation in the treatment of actinomycetoma resistant to conventional treatment. Gac Med Mex 1999;135(5):517-21.